Skip to content
10-K

Annual Report

Revolution Medicines, Inc. RVMD RVMDW

0000950170-25-027736

← back to feed
Filed
Feb 26, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 21, 2025 185.91M sh
Current Liabilities FY 2024 · Dec 31, 2023 $143.85M
Total Liabilities FY 2024 · Dec 31, 2023 $235.51M
Current Assets FY 2024 · Dec 31, 2023 $1.88B
Total Assets FY 2024 · Dec 31, 2023 $2.06B
Shares Diluted FY 2024 · Dec 31, 2022 80.63M sh
Capex FY 2024 · Dec 31, 2022 $10.82M
Operating Cash Flow FY 2024 · Dec 31, 2022 −$224.4M
Cash And Equivalents FY 2024 · Dec 31, 2022 $161.41M
Eps Diluted FY 2024 · Dec 31, 2022 −$3.08
Eps Basic FY 2024 · Dec 31, 2022 −$3.08
Sga Expense FY 2024 · Dec 31, 2022 $40.59M
Rd Expense FY 2024 · Dec 31, 2022 $253.07M
Net Income FY 2024 · Dec 31, 2022 −$248.71M
Operating Income FY 2024 · Dec 31, 2022 −$258.28M
Revenue FY 2024 · Dec 31, 2022 $35.38M
Stockholders Equity FY 2024 · Dec 31, 2021 $602.57M